Spend less on older therapies and the new ones will be more affordable

August 29, 2011 By Philip Clarke
New medicines and therapies place significant financial pressure on the PBS.

Australians are living longer largely due to a remarkable trend that appeared about 40 years ago.

While increased dramatically in the early part of the 20th century, it remained relatively stable for several decades. However, since the 1970s it has been increasing by about a year each decade, mainly due to declines in cardiovascular disease.

While this reduction can be attributed to many factors, including changes in diet and a drop in smoking rates, it is also due to widespread use of drugs to reduce and cholesterol. Several million use these medications daily.

All this has come at a cost. Government expenditure on the Pharmaceutical Benefits Scheme, which provides subsidies for many commonly used medications, has almost doubled in real terms during the past decade.

An important driver of PBS expenditure has been a succession of blockbuster drugs, particularly for treating cardiovascular disease. What popularised them was evidence from large studies demonstrating substantially reduced risk of heart attacks and strokes.

But about 10 years ago, clinical studies started to find something unexpected. One of the first was the ALLHAT study involving different types of blood pressure treatment: its results showed newer medications were no more effective than older, cheaper ones.

Since then several studies of have failed to demonstrate benefit or in some cases showed them to be harmful. The wave of innovation in , at least for the moment, seems to have reached a high-water mark.

With no new blockbuster drugs for cardiovascular disease emerging, the innovative end of the has focused on other diseases such as prevention and . Here there have been important developments, including Gardasil, the Australian-developed vaccine for preventing . New drugs create pressures on the PBS; for example, the cost of providing this vaccine is more than $400 million.

Where can governments find the money to continue to list new medications on the PBS that are shown to be cost-effective? There is a strikingly obvious answer -- pay less for the older generation of medications.

This solution is particularly relevant now, as many blockbuster drugs are coming off patent and so should be subject to dramatic price cuts. Most of the high cost of newer drugs arises not because they are expensive to manufacture, but time-consuming to develop. Hence, when a drug patent expires, its price should fall by up to 95 percent.

Not only will these price reductions benefit consumers, they are a necessary driver of structural change in the pharmaceutical industry. Resources need to be shifted from treatments for , where we can increasingly rely on cheap generic medications, to diseases such as cancer, where there has been innovation. New cancer treatments can be very expensive, because they are for relatively fewer patients, providing a limited market to offset development costs.

Australia has had few effective mechanisms to bring about price reductions in drugs once their patent expires, and consequently pays some of the highest prices in the world for many generics. Take the cholesterol-lowering simvastatin, the patent of which expired in 2005. In Australia the PBS and consumer payments amount to $30 for a month's supply, while in Britain the equivalent cost is only $3, and $1.50 in New Zealand.

Last year the Department of Health and Ageing entered into a four-year pricing agreement with Medicines Australia, the peak body representing larger pharmaceutical companies. This agreement involved modest initial price cuts and then a system of price disclosure from 2012, where the subsidy for older drugs will be based on average wholesale prices.

Unfortunately, this agreement is more likely to entrench rather than solve Australia's generic pricing problem. The all-time blockbuster cholesterol treatment atorvastatin has cost Australian taxpayers more than $5.7 billion since its listing in the late 90s. When it goes off patent next year, its initial price reduction will be only 16 percent, while Canada has just cut its price by 75 percent.

I have previously estimated that paying above world prices will cost about $1.7bn across the next four years for statins alone. Failure to deal with this appears to be symptomatic of broader policy atrophy. Treasury in its first Intergenerational Report argued PBS spending was a key long-term driver of outlays, but it has been unable to lead effective reform. It's also hard to understand why the government has not referred it to the Productivity Commission.

The key challenge for the government is not to find extra funds for new therapies, but to spend less on existing ones. Sometimes less is more.

Explore further: Americans turn to generic medications in 2010: report

Related Stories

Americans turn to generic medications in 2010: report

April 22, 2011
(Medical Xpress) -- In a new report released by the IMS Institute for Healthcare Informatics, the results show that over 78% of the almost four billion prescriptions written in the U.S. in 2010 were for generic drugs. The ...

Drug prices to plummet in wave of expiring patents

July 25, 2011
The cost of prescription medicines used by millions of people every day is about to plummet. The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, including the top two: cholesterol ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.